Gangrena

Acetyl-L-Carnitine (ALCAR) is a mitochondria-supporting compound that facilitates fatty acid transport into mitochondria and supports mitochondrial bioenergetics in retinal cells. A clinical study (Feher 2005) demonstrated that a combination of ALCAR, CoQ10, and omega-3 fatty acids stabilized visual function in early AMD patients by improving RPE mitochondrial function. It is included in some AMD multi-supplement clinical trial formulations.

Alpha-lipoic acid (ALA) is a universal antioxidant that functions in both aqueous and lipid phases, regenerates other antioxidants including vitamins C and E and glutathione, and chelates redox-active metals. A 2025 network pharmacology and in vivo study identified six ferroptosis-related targets of ALA in AMD and confirmed protective effects in a sodium iodate AMD mouse model. ALA is included in registered AMD supplement clinical trials and is noted alongside taurine and riboflavin as antioxidants used to prevent AMD.

DHA accounts for approximately 20% of retinal weight and is the dominant structural fatty acid in the macula. Population studies show an inverse association between omega-3 intake and AMD risk. Cohort studies and twin studies show that high n-3 PUFA and seafood intake may protect against both early and late AMD; however, RCT results with DHA supplementation are mixed.

Anchovies are specifically identified as a dietary source of omega-3 fatty acids associated with reduced risk of age-related macular degeneration (AMD). Observational studies and some RCTs support an inverse relationship between dietary omega-3 (especially DHA/EPA) intake from oily fish including anchovies and AMD risk.

Astaxanthin is a ketocarotenoid with antioxidant potency approximately 10-fold greater than zeaxanthin and lutein, capable of spanning the full lipid bilayer to protect both hydrophilic and hydrophobic membrane zones. The multicenter CARMIS trial (n=145, 24-month RCT) found a formulation including 4 mg astaxanthin with lutein, zeaxanthin, and antioxidants stabilized visual acuity and improved contrast sensitivity in AMD patients compared to controls.

Beta-carotene (15 mg/day) was one of the four original AREDS formula components tested in the landmark RCT of 3,640 AMD patients, which showed a combined ~25% reduction in progression to advanced AMD. However, AREDS2 found lutein/zeaxanthin to be a safer and equally effective substitute, particularly because beta-carotene increases lung cancer risk in smokers. Beta-carotene is no longer the preferred carotenoid for AMD supplementation but has direct AREDS evidence.

Bilberry (Vaccinium myrtillus) is rich in anthocyanins with potent antioxidant, anti-inflammatory, and vascular-protective properties. Animal studies (OXYS rat model) demonstrated bilberry extract prevented macular degeneration and cataracts. A 2024 PMC review confirmed preclinical evidence that bilberry anthocyanins improve retinal health by reducing oxidative stress and inflammation relevant to AMD progression, though large-scale human RCTs are limited.

Blueberries are rich in anthocyanins (primarily delphinidins and cyanidins) with documented anti-VEGF, antioxidant, and anti-inflammatory effects on retinal tissue. A 2024 PMC review of berries and AMD confirmed that blueberry extracts reduce oxidative stress and inflammation in retinal models and emerging clinical evidence indicates dietary intake of blueberry anthocyanins may enhance visual function and slow AMD progression.

Boxthorn is rich in zeaxanthin, the primary macular pigment, and LBPs protect retinal pigment epithelial cells from oxidative damage relevant to AMD pathogenesis. Clinical reviews identify L. barbarum as having a role in addressing age-related macular degeneration. In vitro studies demonstrate LBP protection against amyloid-beta-induced RPE cell damage, a model of AMD.

Epidemiological and clinical evidence supports a role for DHA and EPA in reducing AMD risk and progression. Population studies show that eating oily fish at least weekly is associated with approximately half the risk of wet AMD. The NIH-sponsored AREDS2 trial tested 650 mg EPA + 350 mg DHA daily in AMD patients.

Beta-carotene was a core component of the original AREDS supplement formula shown in a landmark 11-center double-masked RCT to reduce risk of AMD progression by approximately 25% in high-risk individuals. Antioxidant supplementation including beta-carotene reduces progression to advanced AMD (adjusted OR ~0.68). However, beta-carotene has since been replaced in AREDS2 by lutein/zeaxanthin due to lung cancer risk in smokers.

Epidemiological data associate high plasma carotenoid levels with reduced risk of age-related macular degeneration (AMD). Carrots contribute beta-carotene and lesser amounts of lutein and zeaxanthin—the two carotenoids that accumulate as macular pigment. Clinical trial evidence (AREDS) supports antioxidant carotenoid supplementation for slowing AMD progression.

DHA is highly concentrated in retinal photoreceptors and observational studies consistently associate higher omega-3 intake with lower risk of age-related macular degeneration. However, the large AREDS2 RCT did not find that omega-3 supplementation significantly slowed AMD progression.

Collard greens provide approximately 14.6mg of lutein plus zeaxanthin per cooked cup — carotenoids that accumulate in the macula and retina to protect against oxidative damage and blue-light toxicity associated with AMD. The CAREDS study (PubMed 16908818, n=1,787 women) found significantly reduced odds of intermediate AMD in women under 75 with high lutein/zeaxanthin intake. AREDS2 clinical trial data also support the protective role of these carotenoids.

Copper was added to the original AREDS formulation (2 mg/day) specifically to counteract the copper-depleting effect of high-dose zinc supplementation, as zinc competitively inhibits copper absorption. Without copper co-supplementation, high zinc intake causes hypocupraemia and associated anemia. Copper is a cofactor for superoxide dismutase (SOD) and is thus part of the standard evidence-based AMD supplement formula. It does not have independent RCT evidence for AMD but is a required component of AREDS therapy.

CoQ10 is a mitochondrial antioxidant cofactor found in the electron transport chain. A clinical study (Feher 2005) demonstrated that a combination of CoQ10, acetyl-L-carnitine, and omega-3 fatty acids stabilized visual functions in early AMD patients by improving mitochondrial function in the RPE. Reviews of AMD antioxidants consistently identify CoQ10 as effective in improving visual function in early AMD. Typical dose in AMD studies: 50–100 mg/day.

Serum BCX levels are significantly lower in patients with exudative AMD compared to controls in case-control studies. Meta-analyses show consistent inverse associations between BCX and AMD risk. Animal data demonstrate BCX protects against light-induced retinal photoreceptor loss through antioxidant and anti-inflammatory mechanisms.

Curcumin, the primary bioactive curcuminoid of turmeric, exerts anti-VEGF, anti-inflammatory, and antioxidant activities directly relevant to AMD pathogenesis. A Phase 2 RCT (n=32, 24-month) found that curcumin alone and as part of the RQC combination reduced drusen volume versus untreated controls. A retrospective case-control study also showed a curcumin-based supplement combined with anti-VEGF injections improved functional outcomes in neovascular AMD.

Blackcurrant extract has shown protective effects against blue-light-induced retinal degeneration in in vitro and in vivo models of dry AMD. Its anthocyanins reduced ROS in retinal pigment epithelial cells by 80.8%. Broader anthocyanin clinical data link high intake to significantly reduced risk of advanced macular degeneration.

Alpha-tocopherol was included in the landmark AREDS trial, where the multi-antioxidant formula (including vitamin E) reduced progression of intermediate AMD by 25%. However, vitamin E alone has not demonstrated significant benefit for AMD prevention or treatment in multiple individual RCTs.

DHA is the most abundant polyunsaturated fatty acid in photoreceptor outer segment membranes and plays structural and anti-inflammatory roles in the retina. Multiple large epidemiological studies and meta-analyses link higher DHA intake to significantly reduced AMD risk, with one 2025 meta-analysis (18 studies) finding an 18% pooled reduction in AMD odds with higher omega-3 intake. A UK Biobank prospective cohort (n=258,350) found each mmol/L rise in plasma DHA reduced AMD risk by 35%.

DHA intake is inversely associated with advanced AMD in several large prospective cohort studies. The NAT2 RCT found DHA+EPA supplementation did not significantly reduce AMD progression overall, but patients maintaining a consistently high EPA+DHA index showed significantly reduced choroidal neovascularization. The AREDS2 trial (DHA+EPA for 5 years) also did not slow progression to advanced AMD. Evidence is mixed but supports a role for high DHA status.

EGCG protects retinal pigment epithelial (RPE) cells from oxidative damage central to AMD pathogenesis, downregulates VEGFA to suppress neovascularization in wet AMD, and protects against UV-induced retinal cell damage. Preclinical evidence is substantial; controlled clinical trials are still needed.

Lutein and zeaxanthin in egg yolk are the carotenoids exclusively found in the human macula; RCTs demonstrate egg consumption raises serum and macular carotenoid levels, and the AREDS2 trial showed dietary lutein and zeaxanthin are associated with reduced risk of advanced AMD progression in deficient individuals.

EPA is a long-chain omega-3 fatty acid with potent anti-inflammatory effects relevant to AMD pathophysiology, which involves chronic inflammation and complement dysregulation. Meta-analyses link high EPA intake to reduced AMD risk, and the Blue Mountains Eye Study found high omega-3 (EPA-rich) intake lowered early AMD risk by 60% at 5 years. AREDS observational data showed ~56% lower risk of central geographic atrophy with high EPA intake. AREDS2 included EPA at 350 mg/day in combination with DHA.

Observational evidence consistently shows that people with higher fish and omega-3 intake are less likely to develop age-related macular degeneration (AMD). A systematic meta-analysis found high dietary omega-3 intake associated with a 38% lower risk of developing both early and late AMD. DHA constitutes a major fraction of retinal photoreceptor membrane phospholipids, making omega-3 status mechanistically critical to retinal health.

Ginkgo biloba extract contains flavone glycosides and terpene lactones (ginkgolides, bilobalide) with antioxidant and circulatory-enhancing properties relevant to AMD. A 6-month double-blind, placebo-controlled trial in 20 AMD patients (160 mg/day) reported improved visual acuity in the ginkgo group versus placebo. A Cochrane review identified only two small trials, concluding evidence is promising but insufficient to make definitive recommendations.

Goji berry (Lycium barbarum) contains zeaxanthin dipalmitate and Lycium barbarum polysaccharides (LBPs), both with well-documented retinal protective properties. Preclinical studies show LBPs protect against AMD-related RPE degeneration and complement-mediated damage. A 2024 PMC review of berries and AMD confirmed that goji berry preclinical studies support improved retinal health through reduction of oxidative stress and inflammation.

Preclinical and early clinical evidence indicates grape proanthocyanidins protect the retinal pigment epithelium (RPE) from the oxidative senescence underlying AMD. In vitro, GSPE restored NAD+ via NAMPT and reduced NLRP3 inflammasome activation in aging RPE cells. A grape-supplemented diet protected photoreceptors in an animal model of retinal degeneration. Human clinical evidence is limited to indirect circulatory and anti-oxidant data.

GSE proanthocyanidins modulate retinal pigment epithelium (RPE) cellular senescence through the NAMPT/SIRT1/NLRP3 pathway, protecting against age-related macular degeneration (AMD) in preclinical models. OPCs reduce retinal oxidative stress, a primary driver of AMD. A University of Washington pharmacy review lists macular degeneration treatment among documented uses of GSE.

Vaccinium anthocyanosides have shown preliminary clinical evidence for protective effects against mild retinopathies including macular degeneration, primarily through reduction of oxidative stress in retinal tissue and inhibition of retinal angiogenesis. Huckleberry shares the same anthocyanoside classes responsible for these effects. Evidence is preliminary and largely from small European clinical trials and preclinical studies.

Kale contains the highest lutein content of any vegetable (~39 mg/100 g), along with zeaxanthin. Lutein and zeaxanthin are the only carotenoids that accumulate in the retinal macula. The AREDS2 RCT showed that individuals low in dietary lutein/zeaxanthin who supplemented were ~25% less likely to develop advanced AMD. Regular kale consumption is supported as a dietary strategy for AMD risk reduction.

Lutein is a macular xanthophyll carotenoid that constitutes macular pigment, filtering blue light and acting as an antioxidant in retinal tissue. The landmark AREDS2 randomized clinical trial (4,203 participants, 5-year follow-up) found that lutein/zeaxanthin supplementation reduced progression to advanced AMD and was preferred over beta-carotene. A separate RCT in 108 early AMD patients showed 20 mg/day lutein significantly increased macular pigment optical density (MPOD) over 48 weeks. Typical supplemental dose is 10–20 mg/day.

Lycopene is a carotenoid antioxidant with singlet oxygen quenching activity approximately twice that of beta-carotene. Epidemiological studies associate higher dietary lycopene intake with reduced AMD risk, and it is included in some evidence-based AMD supplement formulas alongside lutein and zeaxanthin. A Japanese case-control study found associations between low carotenoid intake and neovascular AMD, and lycopene appears in clinical trial AMD supplement compositions (e.g., 500 mcg in a registered AMD multivitamin trial NCT03946085).

Melatonin is an endogenous antioxidant hormone produced in the pineal gland that also has ocular production and multiple melatonin receptors in the eye. A small clinical study of approximately 100 AMD patients found that supplementation with melatonin (combined with zinc and selenium) prevented further vision loss and reduced pathological macular changes. Low melatonin levels have been correlated with AMD. A 2024 PMC narrative review identifies melatonin as a promising emerging AMD therapy.

N-Acetyl Cysteine (NAC) is a glutathione precursor with demonstrated protective effects on RPE cells in AMD. A 2019 PMC study using primary human RPE cultures from AMD donors showed NAC pretreatment reduced ROS production, protected against H2O2-induced cell death, improved mitochondrial function, and increased glutathione content specifically in AMD RPE cells. NAC is included in registered AMD supplement clinical trials (NCT03946085 at 500 mg/day).

Omega-3 fatty acids (predominantly DHA and EPA from marine sources) are the most extensively studied dietary fats for AMD. A 2025 systematic review and meta-analysis of 18 studies found a pooled 18% reduction in AMD odds with higher omega-3 intake. The AREDS observational data showed ~25–30% lower risk of advanced AMD with high DHA+EPA intake at 8-12 years. Multiple cohort studies (Women's Health Study, Blue Mountains Eye Study) confirm inverse associations. AREDS2 included omega-3 in its test formula.

Pine bark extract (Pycnogenol) is standardized for oligomeric proanthocyanidins and provides potent antioxidant and microcirculatory benefits. A clinical study found that Pycnogenol supplementation improved retinal blood circulation and visual acuity in AMD patients with early retinal damage, and it is cited by authoritative natural eye care resources as a complement to lutein/zeaxanthin in AMD management. Preclinical studies support its anti-VEGF and anti-inflammatory actions in retinal tissue.

Quercetin is a flavonol with antioxidant, anti-inflammatory, and anti-angiogenic properties relevant to AMD. It was evaluated in a Phase 2 RCT (n=32, 24 months) as part of the RQC combination (resveratrol, quercetin, curcumin) in intermediate AMD, which showed significant reduction in drusen volume versus controls. Quercetin inhibits VEGF, NF-κB, and oxidative stress pathways in RPE cells in preclinical studies.

Resveratrol is a stilbenoid polyphenol with anti-angiogenic, anti-inflammatory, and antioxidant properties that address multiple AMD pathways. A Phase 2 RCT (n=32, 24-month follow-up) testing oral resveratrol, quercetin, and curcumin (RQC) in intermediate AMD patients reported a 2.5% mean decrease in drusen volume in the RQC group vs. a 5% increase in the curcumin-only group, suggesting drusen-reducing potential. Further independent large-scale trials are needed.

Saffron (Crocus sativus) contains the carotenoids crocetin and crocin, which have demonstrated neuroprotective effects on photoreceptors in both animal models and human clinical trials. A randomized double-blind, placebo-controlled crossover RCT (n=30, early AMD) found 20 mg/day saffron for 90 days significantly improved macular cone-mediated electroretinogram parameters and visual acuity. A longitudinal follow-up study showed these benefits were sustained with continued supplementation.

Selenium is an essential trace mineral and cofactor for glutathione peroxidase (GPx), a primary antioxidant enzyme in the retina. Observational studies suggest that adequate dietary selenium intake may reduce AMD risk. A clinical study on AMD used a supplement combining melatonin, zinc, and selenium with documented benefit. Selenium is included in AMD-specific clinical trial supplement formulations, and the Cochrane antioxidant review lists it alongside zinc and vitamins as an antioxidant with observational AMD associations.

Spinach is a primary dietary source of lutein and zeaxanthin, which accumulate in the retinal macula as macular pigment. Cohort studies link higher L/Z intake to lower AMD risk, and RCT data (AREDS2) show supplemental L/Z reduces advanced AMD progression by ~25% in individuals with low dietary L/Z intake.

Taurine is the most abundant free amino acid in the retina, essential for photoreceptor structure, osmoregulation, and antioxidant defense. The TOZAL study (73 dry AMD patients, 6-month double-blind RCT) combined taurine with omega-3, zinc, antioxidants, and lutein, with 77% of supplemented patients showing stabilized or improved visual acuity. A 2025 animal study directly demonstrated taurine supplementation significantly preserved retinal outer nuclear layer thickness in a sodium iodate AMD mouse model.

Vitamin C (ascorbic acid) is an aqueous-phase antioxidant present at high concentrations in ocular tissues and was a core component of the original AREDS formulation. The AREDS RCT (n=3,640, 6.3 years, NEI-sponsored) showed that 500 mg/day vitamin C combined with vitamin E, beta-carotene, and zinc reduced progression to advanced AMD by approximately 25% in high-risk participants. It is also included in the AREDS2 reformulation. Typical clinical dose used in AREDS is 500 mg/day.

Vitamin D has immunomodulatory, anti-inflammatory, and anti-angiogenic properties relevant to AMD pathogenesis. A prospective AREDS-linked study (n=2,146, 9.4-year follow-up) evaluated vitamin D intake and AMD progression. Epidemiological and experimental studies consistently point to vitamin D's role in AMD pathophysiology, and a Japanese case-control study (n=161 AMD cases) found low vitamin D intake significantly associated with neovascular AMD (Trend P=0.002).

Vitamin D3 (cholecalciferol) is the specific form of vitamin D studied in AMD research and included in AMD clinical trial supplement formulations. Observational studies associate adequate vitamin D3 status with lower AMD risk, and a Japanese case-control study linked low vitamin D intake to neovascular AMD. Vitamin D3 at 2000 IU/day was included in the AMD-specific multivitamin RCT (NCT03946085). Its anti-inflammatory and anti-VEGF properties are mechanistically relevant to AMD.

Vitamin E (alpha-tocopherol) is a fat-soluble antioxidant that protects polyunsaturated fatty acids in retinal cell membranes from lipid peroxidation. It was a key component of the AREDS formula, which demonstrated a ~25% reduction in risk of advanced AMD progression in high-risk patients. Observational studies from multiple cohorts associate low vitamin E intake with higher AMD risk. AREDS dose was 400 IU/day.

Watercress consumption doubles plasma lutein (demonstrated in a human RCT), and lutein is clinically proven via AREDS2 and multiple RCTs to reduce AMD progression. Lutein and zeaxanthin are found at high levels in watercress, directly linking it to AMD risk reduction through a well-established carotenoid pathway.

Zeaxanthin is a primary macular pigment carotenoid selectively concentrated in the fovea, where it protects photoreceptors by filtering blue light and quenching singlet oxygen. AREDS2 tested lutein/zeaxanthin in over 4,000 AMD patients and found the combination superior to beta-carotene for reducing progression risk. Epidemiological studies consistently report inverse associations between serum zeaxanthin levels and AMD prevalence. Typical clinical dose is 2–10 mg/day.

Zinc is the most abundant trace mineral in the eye and is concentrated in the RPE-choroid layer. It is an essential cofactor for over 200 enzymes, including retinal dehydrogenase, and constitutes the AREDS formula core ingredient. AREDS demonstrated that zinc alone (80 mg/day) produced a statistically significant ~25% reduction in AMD progression risk. It remains the only mineral with this level of evidence and is included in both AREDS and AREDS2 formulations.

Oligomeric proanthocyanidins (OPCs), found in grape seed extract and pine bark (Pycnogenol), are potent flavonoid antioxidants with vasodilatory and anti-inflammatory properties. EBSCO Research Starters cite 'weak but interesting evidence' that OPCs, like bilberry, may prevent or treat macular degeneration due to their flavonoid content and vascular protective effects. Preclinical studies show grape seed extract may protect against AMD and neurodegenerative processes.